Zacks: Brokerages Expect Horizon Pharma PLC (HZNP) Will Post Earnings of $0.50 Per Share
Analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to announce earnings of $0.50 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Horizon Pharma’s earnings, with the highest EPS estimate coming in at $0.53 and the lowest estimate coming in at $0.47. Horizon Pharma posted earnings of $0.26 per share during the same quarter last year, which would suggest a positive year over year growth rate of 92.3%. The business is expected to issue its next quarterly earnings results before the market opens on Wednesday, November 7th.
On average, analysts expect that Horizon Pharma will report full-year earnings of $1.58 per share for the current year, with EPS estimates ranging from $1.50 to $1.64. For the next fiscal year, analysts expect that the firm will report earnings of $1.86 per share, with EPS estimates ranging from $1.60 to $2.12. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.17. The business had revenue of $302.84 million during the quarter, compared to analyst estimates of $275.51 million. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. Horizon Pharma’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.41 earnings per share.
Shares of NASDAQ HZNP traded up $0.22 during trading hours on Friday, reaching $18.27. The stock had a trading volume of 1,083,819 shares, compared to its average volume of 1,672,029. The company has a current ratio of 1.70, a quick ratio of 1.63 and a debt-to-equity ratio of 2.19. Horizon Pharma has a twelve month low of $12.55 and a twelve month high of $21.25. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 1.24 and a beta of 1.40.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of the stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the completion of the transaction, the executive vice president now directly owns 28,767 shares in the company, valued at $593,463.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. United Services Automobile Association grew its holdings in shares of Horizon Pharma by 11.0% during the second quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 2,679 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Horizon Pharma by 25.9% during the second quarter. SG Americas Securities LLC now owns 16,821 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 3,463 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Horizon Pharma by 17.2% during the second quarter. Amalgamated Bank now owns 25,270 shares of the biopharmaceutical company’s stock worth $418,000 after purchasing an additional 3,711 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Horizon Pharma by 74.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 3,877 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Horizon Pharma by 2.2% during the second quarter. Rhumbline Advisers now owns 185,346 shares of the biopharmaceutical company’s stock worth $3,069,000 after purchasing an additional 3,941 shares during the last quarter. Institutional investors own 87.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Featured Article: How is inflation measured?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.